Health Personalised Cancer Vaccine Meets Safety Bar in Ovarian TrialBy Ailsa HendersonOctober 16, 20260 NeoVax plus nivolumab met feasibility and safety expectations in a phase 1 ovarian cancer trial — a necessary step, not yet evidence of benefit.
